Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies

✍ Scribed by Michael F. Sarosdy; Donald L. Lamm; Howard M. Radwin; Daniel D. Von Hoff

• Publisher: John Wiley and Sons
• Year: 1982
• Tongue: English
• Weight: 796 KB
• Volume: 50
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19821001)50:7<1332::aid-cncr2820500719>3.0.co;2-8

✦ Synopsis

Over the past year, we have attempted to grow both primary and metastatic urologic malignancies using a recently developed human tumor cloning system. Formation of colonies in vitro occurred in 125 of 164 primary tumors (76%), including 34 of 47 uroepithelial cancer specimens, 45 of 50 renal cell cancer specimens, 24 of 33 prostatic cancer specimens, and 22 of 34 testicular cancer specimens. A large percentage of metastatic cancers have also been successfully cultured. Growth sufficient for chemosensitivity testing ranged from 43% of the uroepithelial cancers cultured to 64% of the renal cell cancer specimens cultured. When i n vitro chemosensitivity testing was performed, the i n vifro chemosensitivity results show a striking similarity to clinical response rates for the same agents used for these tumors. Overall the human tumor cloning system appears to be a reasonable model for the study of human urologic malignancies.

Cancer 501332-1338, 1982

ROLOGIC CANCERS, which include malignancies of U the urinary and genital organs in men and the urinary organs in women, account for about 25 percent of all new cancers in men and four percent in women. They cause about 15% of male cancer deaths and three percent of female cancer deaths in the United States.' Except for Wilms' Tumor and testicular carcinoma, predictable effective chemotherapy for urologic cancer

is not yet a reality. There is little to offer the patient who is not surgically cured or who presents with metastatic disease.

The soft agar culture method recently developed by Hamburger and Salmon allows growth of human tumor cells while preventing the growth of In retrospective trials, it has been reported to be predictive of the response of an individual patient's tumor to chemot he rap^.^-' Stanisic and Buick have reported growth of transitional cell carcinoma of the bladder in the clonogenic assay

We now report our experience growing human urologic cancers in this system.